On October 16, 2024, Aimed Alliance submitted a comment to Colorado’s PDAB regarding proposed changes to its Drug Affordability Review Policies and Rules. The comment highlighted concerns about amendments to the orphan drug designation and patient and caregiver input processes. In addition, the letter commends the Board for recognizing how drug prices may affect consumers’ cost-sharing and urges the Board to fully consider these effects when determining affordability and assessing UPL impacts on patient access.
The letter also expresses support for the Board’s decision to consider orphan drug status and consult with the Colorado Rare Disease Advisory Council, but it urges the Board to exclude orphan drugs from PDAB review, citing the limited treatment options and unique research and investment challenges for rare disease patients. Additionally, the letter expresses concern over restricting patient and caregiver engagement to those prescribed the drug under review, as this limits the Board’s understanding of broader access and affordability issues, especially for stigmatized conditions. It advocates for including patient and caregiver advocacy organizations to ensure diverse perspectives are considered. Read the letter here.
Last Updated on November 5, 2024 by Aimed Alliance
